tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Retrognathia D063173 1 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Scorpion Stings D065008 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Garcia CD et al. Renal transplantation in children less than six years old. 2001 Nov-Dec Transplant. Proc. pmid:11750527
Gołębiewska J et al. Tako-tsubo cardiomyopathy on the first day after renal transplantation - case report and literature review. 2014 Transplant. Proc. pmid:25380951
Kamińska D et al. Significant infections after hand transplantation in a Polish population. 2014 Transplant. Proc. pmid:25380943
Todo S et al. Early trials with FK 506 as primary treatment in liver transplantation. 1990 Transplant. Proc. pmid:1689886
Mendez R FK 506 and mycophenolate mofetil in renal transplant recipients: six-month results of a multicenter, randomized dose ranging trial. FK 506 MMF Dose-Ranging Kidney Transplant Study Group. 1998 Transplant. Proc. pmid:9636522
Vanrenterghem Y et al. Co-administration of tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. 1998 Transplant. Proc. pmid:9636523
Marin-Gomez LM et al. Evaluation of clinical safety of conversion to Advagraf therapy in liver transplant recipients: observational study. 2009 Jul-Aug Transplant. Proc. pmid:19715867
Kahl A et al. First results with a quadruple therapy regimen including tacrolimus and mycophenolate mofetil in patients after combined pancreas and kidney transplantation. 1998 Transplant. Proc. pmid:9532149
Bruce DS et al. Effects of tacrolimus, mycophenolate mofetil, and cyclosporine microemulsion on rejection incidence in synchronous pancreas-kidney transplantation. 1998 Transplant. Proc. pmid:9532150
Aktürk S et al. Pregnancy After Kidney Transplantation: Outcomes, Tacrolimus Doses, and Trough Levels. 2015 Transplant. Proc. pmid:26093738
Shoji T et al. Long-term acceptance of porcine pulmonary allografts without chronic rejection. 2005 Jan-Feb Transplant. Proc. pmid:15808551
Ortiz de Urbina J et al. Advagraf de novo in liver transplantation: a single-center experience. 2011 Transplant. Proc. pmid:21486583
Kobayashi M et al. Production of monoclonal antibody against recombinant human FKBP-12 and subcellular localization of FKBP-12 in human mononuclear and polymorphonuclear cells. 1993 Transplant. Proc. pmid:7679832
Kuroki H et al. Effect of FK 506 and donor-specific blood transfusion on the rat composite tissue limb allograft and the mechanism of long-term graft survival. 1993 Transplant. Proc. pmid:7679833
Friob MC et al. A combined HPLC-ELISA evaluation of FK 506 in transplant patients. 1991 Transplant. Proc. pmid:1721265
Mueller AR et al. Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease. 1994 Transplant. Proc. pmid:7527984
Machida M et al. Effect of temperature and hematocrit on plasma concentration of FK 506. 1991 Transplant. Proc. pmid:1721266
Nakajima H and Oka T The inhibition of T-cell-receptor-induced Fas ligand upregulation by cyclosporine and FK 506. 1996 Transplant. Proc. pmid:8623224
Tanabe M et al. The influence of donor and recipient strains in isolated small bowel transplantation in rats. 1994 Transplant. Proc. pmid:7527986
Ko S et al. Different immunosuppressive effects of liposomal FK506 in liver and kidney transplantation. 1996 Transplant. Proc. pmid:8623229
Ichikura H et al. Conversion of renal transplant immunosuppression from tacrolimus (FK 506) to cyclosporine: a single center experience. 2000 Transplant. Proc. pmid:11119911
Qu W et al. Correlation Between Immunosuppressive Therapy and CD4(+) T-Cell Intracellular Adenosine Triphosphate Levels in Liver Transplant Recipients. Transplant. Proc. pmid:27569951
Osako M et al. Alloimmune response may be involved in neointimal hyperplasia in cryopreserved aortic allografts. 2001 Transplant. Proc. pmid:11406250
Cantarovich M et al. Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. 1998 Transplant. Proc. pmid:9636592
Hachida M et al. Combined use of deoxyspergualin and FK 506 for temporary circulatory assist. 1999 Transplant. Proc. pmid:10455968
Martín-Mateos RM et al. Initial immunosuppression with or without basiliximab: a comparative study. 2012 Transplant. Proc. pmid:23146457
Gonzalez-Molina M et al. Mycophenolate mofetil and tacrolimus reduce mortality after deceased donor kidney transplantation. 2012 Transplant. Proc. pmid:23146459
Nakamuta M et al. Cyclosporine suppresses cell growth and collagen production in hepatic stellate cells. 2005 Transplant. Proc. pmid:16387179
Kim HC et al. Primary immunosuppression with tacrolimus in kidney transplantation: three-year follow-up in a single center. 2004 Transplant. Proc. pmid:15518753
Yoshimura N et al. Combination therapy of tacrolimus (FK506) with azathioprine and steroids in renal transplant recipients. 1998 Transplant. Proc. pmid:9474949
McKenna BA et al. Tacrolimus (FK 506): a whole blood assay as measured on the Abbott IMx analyzer. 1996 Transplant. Proc. pmid:8623491
Tanida I et al. Yeast cyclophilin-related gene encodes a nonessential second peptidyl-prolyl cis-trans isomerase associated with the secretory pathway. 1991 Transplant. Proc. pmid:1721297
Kawaoka T et al. Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report. 2015 Transplant. Proc. pmid:25891736
Fukushima N et al. Role of endothelial apoptosis in delayed xenograft rejection in pig-to-baboon cardiac transplantation. 1999 Transplant. Proc. pmid:10578268
Moffatt SD and Metcalfe SM FK 506 versus cyclosporine in combination with anti-CD4/CD8 monoclonal antibodies. 1999 Transplant. Proc. pmid:10578271
Lischke R et al. Initial single-center experience with sirolimus after lung transplantation. 2006 Transplant. Proc. pmid:17112886
Wang SS et al. Heart transplantation under cyclosporine or tacrolimus combined with mycophenolate mofetil or everolimus. 2008 Transplant. Proc. pmid:18929814
Alessiani M et al. Total orthotopic small bowel transplantation in swine under FK 506. 1994 Transplant. Proc. pmid:7518148
Ennaifer R et al. Nodular hyperplasia of the gastrointestinal tract after liver transplantation: role of immunosuppressive therapy? A case report. 2015 Transplant. Proc. pmid:25891739
Yang YJ et al. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency. 2008 Transplant. Proc. pmid:18589147
Date K et al. Effect of FK 506 on graft survival in rat small intestinal allografts. 1992 Transplant. Proc. pmid:1376516
Murase N et al. Bone marrow augmentation for heart, liver, and small bowel transplantation: prolongation of graft survival and incidence of graft-versus-host disease. 1995 Transplant. Proc. pmid:7533386
Ishibashi M et al. Effect of FK 506 on generation of activated macrophages invading rejected skin allografts in rats: discrepancy of in vitro versus in vivo effects. 1991 Transplant. Proc. pmid:1721330
Izuishi K et al. Effect of an immunosuppressive agent, tacroliums (FK-506), on the activities of cytochrome P-450-linked monooxygenase systems of rat liver microsomes. 2003 Transplant. Proc. pmid:12591538
Kindt MV et al. Tacrolimus toxicity in rhesus monkey: model for clinical side effects. 1999 Transplant. Proc. pmid:10616519
Varo E et al. Alternative immunosuppression for acute renal failure in liver transplantation: role of ultra-low dose tacrolimus and basiliximab. 2002 Transplant. Proc. pmid:12176471
Braun F et al. How to handle mycophenolate mofetil in combination with tacrolimus? 1998 Transplant. Proc. pmid:9865309
Wasiak D et al. Delayed, Uncommon Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Case Report. 2016 Transplant. Proc. pmid:27496507
Numakura K et al. Incidence and risk factors of clinical characteristics, tacrolimus pharmacokinetics, and related genomic polymorphisms for posttransplant diabetes mellitus in the early stage of renal transplant recipients. 2005 Transplant. Proc. pmid:15919487
Krämer BK et al. Cardiovascular risk estimates and risk factors in renal transplant recipients. 2005 Transplant. Proc. pmid:15919488
Moro JA et al. Randomized prospective study of the evolution of renal function depending on the anticalcineurin used. 2008 Transplant. Proc. pmid:19010143
Hanafusa T et al. Long-term impact of hepatitis virus infection on kidney transplant recipients and a pilot study of the effects of interferon alpha on chronic hepatitis C. 1995 Transplant. Proc. pmid:7533440
Ye Q et al. Persistence of donor cells and incidence of graft-versus-host disease after simultaneous small bowel and bone marrow transplantation. 1996 Transplant. Proc. pmid:8907895
Shapiro R et al. FK 506 in clinical kidney transplantation. 1991 Transplant. Proc. pmid:1721361
Gruttadauria S et al. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation. 2005 Jul-Aug Transplant. Proc. pmid:16182762
Todo S et al. One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. 1991 Transplant. Proc. pmid:1703340
Gojowy D et al. High Frequency of Arterial Hypertension in Patients After Liver Transplantation. 2016 Transplant. Proc. pmid:27496479
Hernández D et al. Cardiovascular risk profile in nondiabetic renal transplant patients: cyclosporine versus tacrolimus. 2003 Transplant. Proc. pmid:12962773
Craig AM et al. A cost-effectiveness analysis of tacrolimus versus cyclosporine microemulsion following kidney transplantation. 2002 Transplant. Proc. pmid:12176519
Takeda M et al. Immunologic factors contributing to acute rejection in lungs xenotransplanted between primates. 1998 Transplant. Proc. pmid:9838670
Murase N et al. Immunomodulation of intestinal transplant with allograft irradiation and simultaneous donor bone marrow infusion. 1999 Feb-Mar Transplant. Proc. pmid:10083238
Nishioka T et al. Arterial stiffness after successful renal transplantation. 2008 Transplant. Proc. pmid:18790249
Gassel HJ et al. Selective immunosuppression induces tolerance after liver transplantation: an immunohistochemical and cytofluorographic analysis of the graft and recipient immune system. 1997 Feb-Mar Transplant. Proc. pmid:9123253
Scott-Douglas N et al. Treatment of acute renal transplant rejection with FK 506 in patients on cyclosporine after failure of standard antirejection therapy. 1996 Transplant. Proc. pmid:8962226
Yokota K et al. Comparative studies of FK506 and cyclosporine in canine orthotopic hepatic allograft survival. 1989 Transplant. Proc. pmid:2468209
Carroll PB et al. Synexin: a target protein for toxic effects of cyclosporine and FK 506 in endocrine cells. 1991 Transplant. Proc. pmid:1721394
Gu B et al. Exploration of Fecal Microbiota Transplantation in the Treatment of Refractory Diarrhea After Renal Transplantation. 2018 Transplant. Proc. pmid:29880353
Mohacsi P et al. Immunosuppression in ABO-incompatible transplantation. 2001 Transplant. Proc. pmid:11377508
Artz MA et al. Randomized conversion from cyclosporine to tacrolimus in renal transplant patients: improved lipid profile and unchanged plasma homocysteine levels. 2002 Transplant. Proc. pmid:12176579
Jonas S et al. Corticosteroid-free therapy after tacrolimus-based dual immunosuppression versus cyclosporine-based quadruple-induction therapy. 2001 Transplant. Proc. pmid:11377511
Boucher A et al. Impact of immunosuppressive regimen on cardiovascular risk factors in kidney transplant recipients. 2002 Transplant. Proc. pmid:12176582
Opelz G New immunosuppressants and HLA matching. 2001 Feb-Mar Transplant. Proc. pmid:11266911
Jiang H et al. IL-10: a tacrolimus-specific cytotoxic mediator in ongoing allograft rejection. 2001 Feb-Mar Transplant. Proc. pmid:11266931
Fu F et al. Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts. 1999 Feb-Mar Transplant. Proc. pmid:10083555
Cirocco RE et al. Kidney recipient CMV incidence in the gancyclovir era: monitoring viral DNA by a CMV-PCR assay. 1999 Feb-Mar Transplant. Proc. pmid:10083604
Budde K et al. Long-term outcome of tacrolimus rescue therapy in late rejection after renal transplantation. 1998 Transplant. Proc. pmid:9723280
Levy GA Neoral is superior to FK 506 in liver transplantation. 1998 Transplant. Proc. pmid:9723293
Weir MR Optimizing early de novo immunosuppression with sirolimus. 2008 Transplant. Proc. pmid:19100903
Chang HR et al. Sirolimus addition is beneficial for renal allograft dysfunction due to simultaneous acute rejection episode and calcineurin inhibitor nephrotoxicity. 2004 Transplant. Proc. pmid:15621119
Takeda M et al. Pretreatment with splenectomy and FK506 in xeno-lung transplantation. 1996 Transplant. Proc. pmid:8658728
Langrehr JM et al. Indefinite small bowel allograft survival after limited immunosuppressive therapy is not due to specific hyporesponsiveness. 1991 Transplant. Proc. pmid:1721425
Zou XM et al. Immunosuppressive effect of FK506 on orthotopic liver and small bowel xenotransplantation (xenoOLTx and SBTx). 1996 Transplant. Proc. pmid:8658729
Lorenzini S et al. Posttransplant lymphoproliferative disorders in liver transplanted patients: a report of four cases. 2006 Transplant. Proc. pmid:16797338
Honbo T et al. The oral dosage form of FK-506. 1987 Transplant. Proc. pmid:2445068
Asensio M et al. Induction with basiliximab reduces acute rejection in pediatric liver transplant patients treated with tacrolimus and steroids. 2002 Transplant. Proc. pmid:12176650
Sperschneider H A large, multicentre trial to compare the efficacy and safety of tacrolimus with cyclosporine microemulsion following renal transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267291
Dumortier J et al. Introduction of mycophenolate mofetil in maintenance liver transplant recipients: what can we expect? Results of a 10-year experience. 2010 Transplant. Proc. pmid:20832553
Shapiro R Tacrolimus in solid organ transplantation: an update. 1999 Transplant. Proc. pmid:10500545
Martins L et al. Conversion to tacrolimus in case-problem kidney transplant recipients under cyclosporine-based immunosuppression. 2000 Transplant. Proc. pmid:11134735
Hanack U et al. Is there a different impact of cyclosporine versus tacrolimus on delayed graft function after kidney transplantation? 1998 Transplant. Proc. pmid:9723477
Valenzuela M et al. Early steroid withdrawal in pediatric renal transplantation at a single center: preliminary report. 2008 Transplant. Proc. pmid:19010242
Aidong W et al. Therapeutic drug monitoring of tacrolimus in early stage after heart transplantation. 2004 Transplant. Proc. pmid:15561258
Ito Y et al. Complete replacement of tracheal epithelia by the host promotes spontaneous acceptance of orthotopic tracheal allografts in rats. 2004 Transplant. Proc. pmid:15561264
Mochizuki M et al. A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease. Japanese FK 506 Study Group on Refractory Uveitis. 1991 Transplant. Proc. pmid:1721456
Barten MJ et al. Assessment of immunosuppression by lymphocyte functions in human blood. 2002 Transplant. Proc. pmid:12431640
Reimer J et al. Quality of life after kidney transplantation--the impact of tacrolimus. 2001 Feb-Mar Transplant. Proc. pmid:11267573
Fritsche L et al. Conversion to mycophenolate mofetil for chronic progressive deterioration of renal allograft function: first clinical experiences in 44 patients. 1998 Transplant. Proc. pmid:9636481
Soh KS et al. Simultaneous liver and kidney transplantation from different living donors. 2012 Transplant. Proc. pmid:22410057
Wojciechowski D et al. Mycophenolate Mofetil Withdrawal With Conversion to Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients. 2017 Transplant. Proc. pmid:28923623
Takaya S et al. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. 1991 Transplant. Proc. pmid:1703691